Research Article

Association between Accessory Gene Regulator Polymorphism and Mortality among Critically Ill Patients Receiving Vancomycin for Nosocomial MRSA Bacteremia: A Cohort Study

Angélica Cechinel,¹ Denise P. Machado,¹ Eduardo Turra,¹ Dariane Pereira,¹
Rodrigo P. dos Santos,² Regis G. Rosa,¹ and Luciano Z. Goldani¹

¹Infectious Diseases Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil

²Hospital Infection Control Section, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, 90035-903 Porto Alegre, RS, Brazil

Correspondence should be addressed to Luciano Z. Goldani; lgoldani@ufrgs.br

Received 19 March 2015; Accepted 23 September 2015

Copyright © 2016 Angélica Cechinel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Polymorphism of the accessory gene regulator group II (*agr*) in methicillin-resistant *Staphylococcus aureus* (MRSA) is predictive of vancomycin failure therapy. Nevertheless, the impact of group II *agr* expression on mortality of patients with severe MRSA infections is not well established. **Objective.** The goal of our study was to evaluate the association between *agr* polymorphism and all-cause in-hospital mortality among critically ill patients receiving vancomycin for nosocomial MRSA bacteremia. **Methods.** All patients with documented bacteremia by MRSA requiring treatment in the ICU between May 2009 and November 2011 were included in the study. Cox proportional hazards regression was performed to evaluate whether *agr* polymorphism was associated with all-cause in-hospital mortality. Covariates included age, APACHE II score, initial C-reactive protein plasma levels, initial serum creatinine levels, vancomycin minimum inhibitory concentration, vancomycin serum levels, and time to effective antibiotic administration. **Results.** The prevalence of group I and group II *agr* expression was 52.4% and 47.6%, respectively. Bacteremia by MRSA group III or group IV *agr* was not documented in our patients. The mean APACHE II of the study population was 24.3 (standard deviation 8.5). The overall cohort mortality was 66.6% (14 patients). After multivariate analysis, initial plasma C-reactive protein levels ($P = 0.01$), initial serum creatinine levels ($P = 0.008$), and expression of group II *agr* ($P = 0.006$) were positively associated with all-cause in-hospital mortality. Patients with bacteremia by MRSA with group II *agr* expression had their risk of death increased by 12.6 times when compared with those with bacteremia by MRSA with group I *agr* expression. **Conclusion.** Group II *agr* polymorphism is associated with an increase in mortality in critically ill patients with bacteremia by MRSA treated with vancomycin.

1. Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) is well recognized as a major cause of nosocomial infection worldwide. Its strong adaptive power to antibiotics has resulted in the emergence of methicillin-resistant *S. aureus* (MRSA) [1, 2]. Resistance to methicillin and other β -lactam antibiotics is caused by the *mecA* gene, which is situated on a mobile genetic element, the staphylococcal cassette chromosome *mec* (SCC*mec*) [3]. Although the origin of MRSA is not fully understood, it is suspected that methicillin-susceptible

S. aureus (MSSA) acquired the *mecA* gene through horizontal transfer from coagulase-negative staphylococci. Recent studies have shown that overall in-hospital mortality rates for patients with bloodstream infections due to MRSA are in the range of 30% but can be as high as 65% in some centers [4, 5]. A thorough knowledge of the epidemiology and the molecular epidemiology of MRSA strains is required to develop effective strategies to prevent the spread of MRSA.

The aim of the present study was to evaluate the association between *agr* polymorphism and all-cause in-hospital

mortality among critically ill patients receiving vancomycin for nosocomial MRSA bacteremia.

2. Methods

A retrospective cohort was performed at a 30-bed general intensive care unit (ICU) of an 845-bed, university-affiliated tertiary care hospital located in the southernmost state of Brazil. The medical records of all cases of documented bacteremia by MRSA requiring vancomycin treatment in the ICU between May 2009 and November 2011 were evaluated. MRSA bacteremia was defined as the presence of at least one positive blood culture for MRSA in a blood sample from a patient with clinical findings consistent with infection [6]. Blood cultures were performed by inoculating 5–10 mL of blood into a flask of the automatic commercial system Bactec/Alert® (Vitek system). Positive cultures were further subcultured in Mueller-Hinton agar (Isofar Ltd., Brazil) supplemented with 5% of human blood and incubated for 24–48 h at $35 \pm 2^\circ\text{C}$ in the hospital microbiology laboratory. Initial susceptibility testing for oxacillin resistance was performed according to CLSI guidelines, using a 30 µg cefoxitin disc in Mueller-Hinton agar [7]. Individual isolates were stored in trypticase soy broth with 20% glycerol at -80°C until MIC testing was performed. MICs for vancomycin, daptomycin, linezolid, quinupristin-dalfopristin, and tigecycline were determined by the Etest (bioMérieux), according to the manufacturer's guidelines (AB Biodisk). Daptomycin, quinupristin-dalfopristin, and linezolid resistance were defined as an isolate with an MIC greater than 1 mcg/mL, 1 mcg/mL, and 4 mcg/mL, respectively [7, 8]. There are currently no recommended CLSI (Clinical and Laboratory Standards Institute) interpretative criteria for tigecycline. In addition, the MICs of vancomycin were determined in duplicate by reference broth microdilution method, as recommended by CLSI, using in-house prepared panels. The following dilutions of vancomycin were tested: 16, 8, 4, 2, 1, 0.5, 0.25, and 0.125 mcg/mL. According to current CLSI criteria, vancomycin-intermediate *S. aureus* and vancomycin-resistant *S. aureus* are currently defined using BMD as exhibiting vancomycin MICs of 4 to 8 mcg/mL and ≥ 16 mcg/mL, respectively. The Etest procedure was performed using a suspension of each isolate in Mueller-Hinton broth, adjusted to the density of a 0.5 McFarland standard, and was swabbed in three directions to ensure uniform growth onto Mueller-Hinton agar plates. The MIC was read where inhibition of growth intersected the Etest strip. When small colonies grew within the zone of inhibition or a haze of growth occurred around MIC endpoints, the highest MIC intersection was recorded. MRSA isolates were characterized by molecular typing techniques. The typing of staphylococcal cassette chromosome *mec* (SCC*mec*) was performed using the multiplex PCR method described by Boye et al.; four sets of primers were used for amplification of the target DNA [9]. PCR was also used to characterize accessory gene regulator (*agr*) based on the method described by Gilot et al., who developed a method for typing of *agr* group by a PCR reaction involving a primer common to all groups and four primers, specific for each group *agr* (*agr* I–IV) [10].

FIGURE 1: Distribution of specific antibiotic minimum inhibitory concentrations (MICs) by Etest for MRSA blood isolates.

2.1. Statistical Analysis. The results were described as frequency (%) in the case of discrete variables. Clinical and microbiological characteristics and therapeutic interventions were included in the univariate and multivariate analyses. Cox proportional hazards regression was performed to evaluate whether *agr* polymorphism (determined by PCR) was associated with all-cause 30-day hospital mortality. Covariates included age, APACHE II score (acute physiological assessment and chronic health evaluation), initial C-reactive protein plasma levels, initial serum creatinine levels, vancomycin minimum inhibitory concentration, and time to effective antibiotic administration. All variables with a *P* value < 0.10 in the univariate analysis were included in the stepwise multiple logistic regression to identify potential factors associated with mortality. In the multivariate model, independent variables were eliminated from the highest to the lowest *P* value but remained in the model if the *P* value was < 0.05 .

The study was approved by the Ethics and Research Committee of Hospital de Clínicas de Porto Alegre, Brazil. Because no direct patient contact was planned, the requirement for informed consent was waived.

3. Results

In total, 21 patients with MRSA bacteremia were evaluated during the study period. The baseline characteristics are shown in Table 1. The prevalence of group I and group II *agr* expression was 52.4% and 47.6%, respectively. No case of bacteremia by MRSA group III or group IV *agr* was documented. The mean APACHE II of the study population was 24.3 (standard deviation 8.5). The overall cohort mortality was 66.6% (14 patients). Distribution of specific antibiotic minimum inhibitory concentrations (MICs) to vancomycin, linezolid, daptomycin, quinupristin-dalfopristin, and tigecycline for MRSA blood isolates is presented in Figure 1. MRSA isolates were overall susceptible for all the antimicrobials. The majority of the MRSA isolates presented vancomycin MICs by Etest testing between 1.0 and 1.5 mcg/mL. The MICs

TABLE 1: Characteristics of the patients with MRSA bacteremia.

Variable	N (%)
Age years, mean (SD)	55.5 (17.2)
Female sex, number (%)	9 (45.0)
Type of underlying disease, number (%)	
Diabetes mellitus	6 (28.6)
Malignancy	5 (23.8)
Cardiac failure	3 (14.3)
Chronic renal failure	3 (14.3)
Chronic obstructive pulmonary disease	2 (9.5)
HIV	2 (9.5)
APACHE II score, mean (SD)	24.3 (8.5)
Initial plasma CRP, mg/L, mean (SD)	178.6 (110.8)
Initial serum creatinine, g/dL, mean (SD)	1.7 (1.3)
Genotypic characteristic of blood isolates, number (%)	
agr group	
I	11 (52.4)
II	10 (47.6)
III	0 (0)
IV	0 (0)
SCCmec type	
I	2 (9.5)
II	0 (0)
III	5 (23.8)
IV	3 (14.3)
ND	11 (52.4)
Overall in-hospital mortality, number (%)	14 (66.6)

Note. SD: standard deviation; CRP: C-reactive protein; agr: accessory gene regulator; SCCmec: staphylococcal cassette chromosome mec; ND: not determined.

for vancomycin determined using the broth microdilution method were ≤ 1.0 mcg/mL. Univariate analysis of possible relevant factors in patients associated with mortality in patients with MRSA bacteremia is shown in Table 2. After multivariate analysis, initial plasma C-reactive protein levels ($P = 0.10$), initial serum creatinine levels ($P = 0.008$), and expression of group II agr ($P = 0.006$) were positively associated with all-cause in-hospital mortality (Table 3). Patients with bacteremia by MRSA with group II agr expression had their risk of death increased by 12.6 times when compared with those with bacteremia by MRSA with group I agr expression. In-hospital mortality of critically ill patients with MRSA bacteremia treated with vancomycin according accessory gene regulator (agr) polymorphism is shown in Figure 2.

4. Discussion

MRSA comprised nearly 60% of *S. aureus* organisms isolated in US intensive care units (ICUs) in 2003 [11]. In Latin America, rates of MRSA surpassed 50% in over half of the

countries, and a similar situation was observed in many institutions from the Asia-Pacific region [12]. In Brazil, the Antimicrobial Surveillance Program (SENTRY) described a prevalence of MRSA bacteraemia of 30.9% in hospitalized patients between 1997 and 2000, but in large Brazilian teaching hospitals, up to 73% of clinically significant *S. aureus* bacteremia was caused by methicillin-resistant strains [13, 14].

Our patients were infected with MRSA isolates presenting low MICs against vancomycin. Therefore, we could not find any association between 30-day mortality and MRSA vancomycin MICs. Even considering the important comorbidities and high APACHE II scores typically present in ICU patients, the overall mortality of our patients with MRSA bacteremia treated with vancomycin was considered high. Recently, infections due to isolates with high but susceptible vancomycin MICs have been associated with additional treatment failures and patient mortality [15].

On the other hand, a recent meta-analysis has shown that there were no statistically significant differences in the risk of death when comparing patients with *S. aureus* exhibiting high-vancomycin MIC to those with low-vancomycin MIC (< 1.5 mcg/mL) [16]. These poorer outcomes may in part be explained by severity of comorbidities and inability of attaining appropriate vancomycin levels in these patients. However, assumptions that these poor outcomes are solely due to failure to achieve optimal serum levels of vancomycin are premature. The availability of effective alternatives further erodes the position of vancomycin as first-line therapy. The emergence of resistance and cost considerations, however, favor a more measured approach when using alternative antimicrobials. However, our MRSA isolates did not present MICs > 2 mcg/mL and the serum levels of vancomycin attained by our patients were within the optimal range of 15.0–20.0 μ g/mL (data not shown). In addition, all MRSA strains isolated from the blood of our patients were susceptible to the available alternative antimicrobials. Although uncommon, it is important to mention that MRSA resistance to new antibiotics such as linezolid and daptomycin has been described in clinical settings [17, 18].

In our study, agr II MRSA was associated with increased mortality in patients with bacteremia. The accessory gene regulator (Agr) is a quorum-sensing regulator in *S. aureus* that is responsible for biofilm production and the expression of adherence and virulence factors. Previous studies have found that MRSA isolates with an agr II polymorphism may influence the clinical efficacy of vancomycin [19, 20]. SCCmec type II has been shown to be a marker for disease severity and mortality [21]. Most of our MRSA isolates were nontypeable (53%). Eleven isolates (38%) carried SCCmec element types III and IV. Because of the small sample sizes, we could not evaluate in our multivariable logistic regression model the association of SCCmec type with hospital mortality.

Several points must be considered when analyzing our data. We were not able to control for other mortality risk factors in our sample. In addition, the observations in this study are subject to limitations due to the fact that the data was obtained from a retrospective analysis.

TABLE 2: Univariate Cox regression analysis of risk factors for in-hospital mortality in critically ill patients with MRSA bacteremia treated with vancomycin.

Variable	Mortality group (<i>n</i> = 14)	Survival group (<i>n</i> = 7)	HR (95% CI)	<i>P</i> value
Age years, median (SD)	57.1 (13.6)	52.4 (23.8)	1.01 (0.97–1.05)	0.47
APACHE II score, median (SD)	25.0 (9.1)	23.1 (7.8)	1.01 (0.93–1.11)	0.69
Initial plasma CRP, mg/L, median (SD)	226.0 (100.5)	90.6 (69.2)	1.004 (0.99–1.009)	0.07
Initial serum creatinine, g/dL, mean (SD)	1.9 (1.2)	1.2 (1.4)	1.42 (0.99–2.04)	0.05
MIC for vancomycin > 1 mcg/mL, No (%)	1 (7.1)	4 (57.1)	0.23 (0.03–1.85)	0.17
Appropriate vancomycin serum trough levels, number (%)	8 (57.1)	2 (14.2)	3.05 (0.37–25.11)	0.29
Time to vancomycin administration, days, mean (SD)	0.38 (0.96)	2.33 (2.33)	0.66 (0.37–1.16)	0.15
Group II <i>agr</i> specificity, number (%)	8 (57.1)	2 (28.5)	2.80 (0.84–9.38)	0.09

Note. HR: hazard ratio; 95% CI: 95% confidence interval; SD: standard deviation; CRP: C-reactive protein; MIC: minimum inhibitory concentration; *agr*: accessory gene regulator.

FIGURE 2: In-hospital mortality of critically ill patients with MRSA bacteremia treated with vancomycin according accessory gene regulator (*agr*) polymorphism. Values expressed as deaths/survival cases.

TABLE 3: Multivariate Cox regression analysis of factors associated with in-hospital mortality in critically ill patients with MRSA bacteremia treated with vancomycin.

Variable	Adjusted HR	95% CI	<i>P</i> value
Initial plasma CRP, mg/L	1.01	1.002–1.019	0.01
Initial serum creatinine, g/dL	2.11	1.21–3.68	0.008
Group II <i>agr</i> specificity	12.60	2.07–76.69	0.006

Note. HR: hazard ratio; 95% CI: 95% confidence interval; CRP: C-reactive protein; *agr*: accessory gene regulator.

In conclusion, expression of group II *agr* poses risk for mortality in critically ill patients with bacteremia by MRSA treated with vancomycin. Alternative antimicrobial agents including daptomycin and linezolid for treatment of MRSA bacteremia expressing group II *agr* should be considered in this setting.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

This study was supported in part by CNPq (Brazilian Council of Research) and FIPE (grant support of Hospital de Clínicas de Porto Alegre).

References

- [1] M. E. Stryjewski and G. R. Corey, "Methicillin-resistant *Staphylococcus aureus*: an evolving pathogen," *Clinical Infectious Diseases*, vol. 58, supplement 1, pp. S10–S19, 2014.
- [2] I. M. Gould, "MRSA bacteraemia," *International Journal of Antimicrobial Agents*, vol. 30, supplement 1, pp. 66–70, 2007.
- [3] R. Ganga, K. Riederer, M. Sharma et al., "Role of SCCmec type in outcome of *Staphylococcus aureus* bacteremia in a single medical center," *Journal of Clinical Microbiology*, vol. 47, no. 3, pp. 590–595, 2009.
- [4] M. E. A. de Kraker, M. Wolkewitz, P. G. Davey, and H. Grundmann, "Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay

- related to methicillin-resistant *Staphylococcus aureus* bloodstream infections,” *Antimicrobial Agents and Chemotherapy*, vol. 55, no. 4, pp. 1598–1605, 2011.
- [5] J. Gómez, E. García-Vázquez, R. Baños et al., “Predictors of mortality in patients with methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia: the role of empiric antibiotic therapy,” *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 26, no. 4, pp. 239–245, 2007.
- [6] M. M. Levy, M. P. Fink, J. C. Marshall et al., “2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference,” *Critical Care Medicine*, vol. 31, no. 4, pp. 1250–1256, 2003.
- [7] Clinical and Laboratory Standards Institute, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard*, CLSI Document M7-A8, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 8th edition, 2008.
- [8] Clinical and Laboratory Standards Institute, *Performance Standards for Antimicrobial Susceptibility Testing. 17th Informational Supplement*, M100-S22, CLSI, Wayne, Pa, USA, 2012.
- [9] K. Boye, M. D. Bartels, I. S. Andersen, J. A. Møller, and H. Westh, “A new multiplex PCR for easy screening of methicillin-resistant *Staphylococcus aureus* SCCmec types I–V,” *Clinical Microbiology and Infection*, vol. 13, no. 7, pp. 725–727, 2007.
- [10] P. Gilot, G. Lina, T. Cochard, and B. Poutrel, “Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of *Staphylococcus aureus* strains isolated from cows with mastitis,” *Journal of Clinical Microbiology*, vol. 40, no. 11, pp. 4060–4067, 2002.
- [11] National Nosocomial Infections Surveillance System, “National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004,” *American Journal of Infection Control*, vol. 32, no. 8, pp. 470–485, 2004.
- [12] M. Guzmán-Blanco, C. Mejía, R. Isturiz et al., “Epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) in Latin America,” *International Journal of Antimicrobial Agents*, vol. 34, no. 4, pp. 304–308, 2009.
- [13] H. Sader, R. N. Jones, A. C. Gales, J. B. Silva, A. C. Pignatari, and SENTRY Participants Group, “SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001,” *Brazilian Journal of Infectious Diseases*, vol. 8, no. 1, pp. 25–79, 2004.
- [14] A. C. Gales, H. S. Sader, J. Ribeiro, C. Zoccoli, A. Barth, and A. C. Pignatari, “Antimicrobial susceptibility of Gram-Positive bacteria isolated in Brazilian hospitals participating in the SENTRY program (2005–2008),” *The Brazilian Journal of Infectious Diseases*, vol. 13, no. 2, pp. 90–98, 2009.
- [15] R. M. Ribas, C. Freitas, and P. P. Gontijo-Filho, “Nosocomial methicillin-resistant *Staphylococcus aureus* bacteremia in a tertiary care hospital: risk factors, overall mortality and antimicrobial resistance,” *International Journal of Medicine and Medical Sciences*, vol. 1, no. 10, pp. 412–417, 2009.
- [16] A. C. Kalil, T. C. Van Schooneveld, P. D. Fey, and M. E. Rupp, “Association between vancomycin minimum inhibitory concentration and mortality among patients with staphylococcus aureus bloodstream infections: a systematic review and meta-analysis,” *The Journal of the American Medical Association*, vol. 312, no. 15, pp. 1552–1564, 2014.
- [17] B. Gu, T. Kelesidis, S. Tsiodras, J. Hindler, and R. M. Humphries, “The emerging problem of linezolid-resistant *Staphylococcus*,” *Journal of Antimicrobial Chemotherapy*, vol. 68, no. 1, pp. 4–11, 2013.
- [18] J. B. Patel, L. A. Jevitt, J. Hageman, L. C. McDonald, and F. C. Tenover, “An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in *Staphylococcus aureus*,” *Clinical Infectious Diseases*, vol. 42, no. 11, pp. 1652–1653, 2006.
- [19] P. A. Moise-Broder, G. Sakoulas, G. M. Eliopoulos, J. J. Schentag, A. Forrest, and R. C. Moellering Jr., “Accessory gene regulator group II polymorphism in methicillin-resistant *Staphylococcus aureus* is predictive of failure of vancomycin therapy,” *Clinical Infectious Diseases*, vol. 38, no. 12, pp. 1700–1705, 2004.
- [20] J. T. de Sanctis, A. Swami, K. Sawarynski et al., “Is there a clinical association of vancomycin MIC Creep, agr Group II Locus, and treatment failure in MRSA bacteremia?” *Diagnostic Molecular Pathology*, vol. 20, no. 3, pp. 184–188, 2011.
- [21] J. H. Han, P. H. Edelstein, W. B. Bilker, and E. Lautenbach, “The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant *Staphylococcus aureus* bacteremia,” *Journal of Infection*, vol. 66, no. 1, pp. 41–47, 2013.